JP2016513685A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513685A5
JP2016513685A5 JP2016502351A JP2016502351A JP2016513685A5 JP 2016513685 A5 JP2016513685 A5 JP 2016513685A5 JP 2016502351 A JP2016502351 A JP 2016502351A JP 2016502351 A JP2016502351 A JP 2016502351A JP 2016513685 A5 JP2016513685 A5 JP 2016513685A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
composition
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513685A (ja
JP6407955B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/027154 external-priority patent/WO2014152278A2/en
Publication of JP2016513685A publication Critical patent/JP2016513685A/ja
Publication of JP2016513685A5 publication Critical patent/JP2016513685A5/ja
Application granted granted Critical
Publication of JP6407955B2 publication Critical patent/JP6407955B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502351A 2013-03-15 2014-03-14 クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法 Expired - Fee Related JP6407955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788398P 2013-03-15 2013-03-15
US61/788,398 2013-03-15
PCT/US2014/027154 WO2014152278A2 (en) 2013-03-15 2014-03-14 Coumarin derivatives and methods of use in treating hyperproliferative diseases

Publications (3)

Publication Number Publication Date
JP2016513685A JP2016513685A (ja) 2016-05-16
JP2016513685A5 true JP2016513685A5 (enExample) 2017-04-20
JP6407955B2 JP6407955B2 (ja) 2018-10-17

Family

ID=51581693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502351A Expired - Fee Related JP6407955B2 (ja) 2013-03-15 2014-03-14 クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法

Country Status (10)

Country Link
US (1) US10369145B2 (enExample)
EP (1) EP2970249A4 (enExample)
JP (1) JP6407955B2 (enExample)
KR (1) KR20150132483A (enExample)
CN (1) CN105246887B (enExample)
AU (1) AU2014240003B2 (enExample)
CA (1) CA2903107C (enExample)
HK (1) HK1218537A1 (enExample)
MX (1) MX379292B (enExample)
WO (1) WO2014152278A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158913A2 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
US9676779B2 (en) 2012-11-20 2017-06-13 Discoverybiomed, Inc. Small molecule CFTR correctors
CA2891965A1 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic cftr correctors
HK1218537A1 (zh) 2013-03-15 2017-02-24 Discoverybiomed Inc. 香豆素衍生物以及用於治疗过度增生性疾病的方法
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
CN105541852B (zh) * 2016-01-29 2017-09-15 扬州大学 2‑(香豆素‑3‑基)‑6‑甲基吡啶并[5,4‑c]香豆素的合成方法
CN107098895B (zh) * 2016-02-19 2020-01-07 湖南大学 苯氨基噻唑甲基喹啉酮衍生物及其制备方法与应用
WO2018237174A2 (en) * 2017-06-21 2018-12-27 The Johns Hopkins University CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS
CN109464440A (zh) * 2019-01-17 2019-03-15 北京大学 3-乙酰氨基香豆素在制备治疗或预防肾脏纤维化及慢性肾病的药物中的应用
CN112274517A (zh) * 2020-10-30 2021-01-29 江苏大学 一种治疗套细胞淋巴瘤的药物组合物
WO2025150943A1 (ko) * 2024-01-09 2025-07-17 주식회사 프로티나 신규 화합물 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566580A (en) 1978-11-11 1980-05-20 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US20060122387A1 (en) 2002-06-13 2006-06-08 Cti Europe S.R.L. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
CN101076332A (zh) 2004-10-13 2007-11-21 Ptc医疗公司 吡唑或三唑化合物及其用于制备治疗体细胞突变相关疾病的药物的用途
JP2008515992A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス,インコーポレーテッド 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
US7799915B2 (en) 2004-10-13 2010-09-21 Wyeth Llc Anilino-pyrimidine analogs
US20090012148A1 (en) 2005-11-01 2009-01-08 Maxfield Frederick R Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
CN101351208A (zh) 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
EP2581451B1 (en) 2007-12-13 2016-03-09 Indiana University Research and Technology Corporation Compounds for inhibiting mammalian s-nitrosoglutathione reductase
US20120100609A1 (en) * 2009-03-27 2012-04-26 Crawford Brett E N-linked glycan biosynthesis modulators
ITMI20111068A1 (it) 2011-06-14 2012-12-15 Azienda Ospedaliera Universitaria I Ntegrata Di Ve Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
HK1218537A1 (zh) 2013-03-15 2017-02-24 Discoverybiomed Inc. 香豆素衍生物以及用於治疗过度增生性疾病的方法

Similar Documents

Publication Publication Date Title
JP2016515131A5 (enExample)
JP2016518328A5 (enExample)
JP2016505614A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2016531121A5 (enExample)
JP2015537008A5 (enExample)
JP2016506958A5 (enExample)
JP2017535614A5 (enExample)
JP2013537203A5 (enExample)
RU2015143841A (ru) Ингибиторы hdac
JP2012508252A5 (enExample)
JP2016514159A5 (enExample)
RU2014114466A (ru) ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА
JP2013525458A5 (enExample)
CY1121320T1 (el) Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων
JP2018533593A5 (enExample)
JP2016531126A5 (enExample)
JP2018504441A5 (enExample)
EA201691618A1 (ru) Способ получения сульфамидных производных пиримидина
JP2013502441A5 (enExample)
JP2014526533A5 (enExample)
JP2015521156A5 (enExample)
JP2016028076A5 (enExample)
JP2015536997A5 (enExample)
JP2015521195A5 (enExample)